PubMed دسترسی آزاد

Pharmacovigilance in medical cannabis therapy among physicians in Poland: pharmacovigilance knowledge, ADR reporting practice and cannabis-related safety reporting.

استودیوی صوتی مقاله

پخش حرفه‌ای فارسی و انگلیسی

در حال بررسی نسخه‌های صوتی ذخیره‌شده…

صوت تولیدشده با هوش مصنوعی است. برای کاربرد علمی یا درمانی، متن و منبع اصلی را بررسی کنید.
خواندن هوشمند فارسی و انگلیسی در حال آماده‌سازی صداهای مرورگر…
تنظیم صدای طبیعی و سرعت

صداهایی که در نامشان «Natural»، «Neural» یا «Online» دیده می‌شود معمولاً طبیعی‌ترند. انتخاب صدا به صداهای نصب‌شده در ویندوز و مرورگر شما بستگی دارد.

چکیده اصلی

BACKGROUND: Medical cannabis is increasingly used in routine care, but its pharmacovigilance profile remains difficult to monitor because products, formulations, doses, routes of administration and clinical indications vary substantially. This study assessed pharmacovigilance knowledge, adverse drug reaction (ADR) reporting practice and attitudes toward medical cannabis among physicians in Poland, with particular attention to factors associated with ADR reporting. METHODS: We conducted a cross-sectional analytical survey among 253 clinically active physicians in Poland using an anonymous self-administered questionnaire. The survey covered demographic and professional characteristics, pharmacovigilance knowledge and awareness, general ADR reporting, clinical exposure to medical cannabis and cannabis-related safety perceptions. Crude associations were examined using chi-square tests, Fisher's exact tests for cannabis-specific sparse-data comparisons, Cramer's V, odds ratios (ORs) and 95% confidence intervals, with Benjamini-Hochberg false-discovery-rate adjustment. For the primary outcome of general ADR reporting, a forced-entry multivariable logistic regression included PV-purpose knowledge, any medical specialization, professional experience greater than 10 years, hospital/university workplace, medical cannabis exposure and sex. Cannabis-specific reporting was analyzed separately using exact methods because only 19 events occurred. RESULTS: Most respondents reported clinical exposure to medical cannabis (81.0%), whereas only 13.4% reported adequate formal education in this area. In crude analysis, knowledge of the purpose of pharmacovigilance showed the strongest association with ADR reporting (OR 46.58; 95% CI 21.20-102.32; p < 0.001; q < 0.001). In the adjusted model, PV-purpose knowledge (adjusted OR [aOR] 24.71; 95% CI 9.40-64.96), any medical specialization (aOR 9.97; 95% CI 3.66-27.20) and hospital/university workplace (aOR 5.72; 95% CI 2.10-15.55) retained positive associations with general ADR reporting. Professional experience greater than 10 years, medical cannabis exposure and sex were not statistically significant after adjustment. Cannabis-specific ADR reporting was uncommon. CONCLUSIONS: In this sample, PV-purpose knowledge, medical specialization and hospital/university workplace retained positive associations with general ADR reporting after multivariable adjustment. Crude associations for longer professional experience and medical cannabis exposure were attenuated after adjustment. The combination of frequent medical cannabis exposure and rare cannabis-specific ADR reporting suggests an exposure-reporting gap. The observational findings support practical, therapy-specific pharmacovigilance training but should not be interpreted causally.

متن کامل اصلی

نسخه دارای مجوز در منبع علمی در دسترس است.

لینک مستقیم از metadata منبع گرفته شده و در تب جدید باز می‌شود.

باز کردن متن کامل

کلیدواژه‌ها

ADR reportingadverse drug reactionsdrug safetymedical cannabispharmacovigilancephysicianspublic healthreal-world evidence
در همین زیرشاخه

مقاله‌های مرتبط

PubMed2026

GLP-1R expression and dermatological diseases: a mendelian randomization and real-world study.

BACKGROUND: Although glucagon-like peptide-1 receptor (GLP-1R) is widely expressed in multiple tissues and organs including skin and subcutaneous tissue, with diverse physiological roles in metabolism and immunity, the potential causal association between GLP-1R expression and dermatological diseases remains unclear. METHODS: Available cis-expression quantitative trait loci (cis-eQTLs) were selected as genetic instruments for GLP-1R ex…

PubMed2026

Machine learning-driven pharmacovigilance of antidiabetic drugs: comparative reporting patterns and classification of serious adverse events.

PURPOSE: This study aims to evaluate the comparative adverse drug event (ADE) reporting patterns associated with antidiabetic drugs and develop machine learning (ML)-based classification models for the seriousness of reported ADEs. METHODS: We performed a retrospective analysis of 28,633 antidiabetic-related ADEs reported to the Korea Institute of Drug Safety and Management- Korea Adverse Event Reporting System database (KAERS DB 2505A…

PubMed2026

Artificial Intelligence Across the Pharmaceutical Life Cycle: Implications for Industry-Based Clinical Pharmacists.

Artificial intelligence (AI) is increasingly shaping the pharmaceutical industry. This ACCP commentary examines the implications of AI for industry-based clinical pharmacists across the pharmaceutical life cycle, including drug development, regulatory affairs, medical affairs, health economics and outcomes research, and pharmacovigilance. Artificial intelligence-enabled tools may support target identification, clinical trial design, re…

PubMed2026

FAERS-based pharmacovigilance study of sevoflurane-associated adverse events: A 20-year comprehensive analysis.

BACKGROUND: Sevoflurane, an ether-derived inhalational anesthetic widely used for general anesthesia, requires comprehensive safety evaluation. OBJECTIVES: This study aimed to identify sevoflurane-associated adverse events and detect unexpected safety signals using data from the FDA Adverse Event Reporting System (FAERS). METHODS: We analyzed FAERS data from the first quarter of 2004 through the first quarter of 2024, applying four dis…